Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection-A Systematic Review

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Focal Epithelial Hyperplasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A Contemporary Systematic Review on Repartition of HPV-Positivity in Oropharyngeal Cancer Worldwide

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. NCBI's Virus Discovery Codeathon: Building "FIVE" -The Federated Index of Viral Experiments API Index

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genomic Alterations in Human Papillomavirus-Positive and -Negative Conjunctival Squamous Cell Carcinomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Systematic review on the current knowledge and use of Single-cell RNA Sequencing in Head and Neck Cancer

    Research output: Contribution to journalReviewResearchpeer-review

  4. Examination of hearing loss among school-aged children in Greenland

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Human papillomavirus (HPV) imposes an increased risk of developing cervical, anal and oropharyngeal cancer. In the Western world, HPV infection is currently the major cause of oropharyngeal cancer. The effectiveness of HPV vaccines for oral or oropharyngeal HPV infection is yet to be determined. This study conducted a systematic literature search in Pubmed and Embase. Studies investigating the impact of HPV vaccines on oral or oropharyngeal HPV infection were enrolled. This review reports the relative prevention percentage (RPP), including a risk of bias assessment as well as a quality assessment study. Nine studies were included (48,777 participants): five cross-sectional studies; one randomized community trial study (RCT); one longitudinal cohort study; and two case-control studies. A significant mean RPP of 83.9% (66.6-97.8%) was calculated from the cross-sectional studies, 82.4% in the included RCT and 83% in the longitudinal cohort study. Further, two case-control studies that measured antibody response in participants immunized with HPV vaccines were included. Respectively, 100% and 93.2% of participants developed HPV-16 Immunoglobulin G (IgG) antibodies in oral fluids post-vaccination. Analysis of the studies identified a significant decrease in vaccine-type oral or oropharyngeal HPV infections in study participants immunized with HPV vaccines across study designs and heterogenous populations. Further, a significant percentage of participants developed IgG antibodies in oral fluid post-vaccination.

Original languageEnglish
Article number1339
JournalViruses
Volume13
Issue number7
ISSN1999-4915
DOIs
Publication statusPublished - 11 Jul 2021

    Research areas

  • Alphapapillomavirus/pathogenicity, Case-Control Studies, Cross-Sectional Studies, Female, Humans, Longitudinal Studies, Male, Mouth Neoplasms/prevention & control, Mouth/virology, Oropharyngeal Neoplasms/prevention & control, Oropharynx/virology, Papillomaviridae/immunology, Papillomavirus Infections/metabolism, Papillomavirus Vaccines/metabolism, Pre-Exposure Prophylaxis/methods, Vaccination, Oncology, Vaccines, Human papillomavirus, Oropharyngeal cancer, Head and neck cancer

ID: 67741959